• Explore /
  • Poster
  • / Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC).

Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC).

Abstract Poster

Authors

null

Trang H. Au

University of Utah, College of Pharmacy, Salt Lake City, UT

Trang H. Au , Erin B. Bailey , Shiven B. Patel , Srinivas Kiran Tantravahi , Neeraj Agarwal , David D. Stenehjem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Citation

J Clin Oncol 34, 2016 (suppl 2S; abstr 610)

DOI

10.1200/jco.2016.34.2_suppl.610

Abstract #

610

Poster Bd #

J7

Abstract Disclosures

Similar Posters

First Author: Lothar Mueller

First Author: Nicholas J. Vogelzang

Poster

2012 Genitourinary Cancers Symposium

Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC).

Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC).

First Author: Michael Roger Harrison

First Author: Pengxiang Li